search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Transfer of multiantigen-specific T cells after allogeneic stem cell transplantation


- candidate number19528
- NTR NumberNTR4801
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR22-sep-2014
- Secondary IDsLUMC 2014-01 
- Public TitleTransfer of multiantigen-specific T cells after allogeneic stem cell transplantation
- Scientific TitleTransfer of Streptamer selected multiantigen-specific T cells to prevent infections and relapse after allogeneic stem cell transplantation
- ACRONYMT control
- hypothesis
- Healt Condition(s) or Problem(s) studiedHemato-oncological patients, Hematological malignancy, Allogeneic stem cell transplantation
- Inclusion criteria- Age 18-75 years
- Planned T cell depleted allo-SCT for one of these diagnoses:
o Acute Lymphoblastic Leukemia in CR after prephase and first induction and consolidation therapy and WBC < 30 x 109/l in B-ALL or < 100 x 109/l in T-ALL at initial diagnosis. ALL with t(9;22), t(4;11), complex karyotype or 11q23 abnormalities will be excluded.
o Acute Myeloid Leukemia in CR excluding AML with:
* Monosomal Karyotype
* Abn3q26
* EVI1 overexpression
o Multiple myeloma at least in stable PR (no treatment foreseen in first 6 months after allo-SCT)
o Non high grade B-NHL (B-CLL, Mantle cell lymphoma, Follicular Lymphoma, MALT, LPL) at least in stable PR (no treatment foreseen in first 6 months after allo-SCT)
o Myeloprolypherative disorder at least in stable PR (no treatment foreseen in first 6 months after allo-SCT), excluding CML blastic phase
o Myelodysplastic syndrome at least in stable PR (no treatment foreseen in first 6 months after allo-SCT)
- HLA type A*0201.
- Written informed consent of the patient
- Availability of a stem cell donor who meets the following inclusion criteria:
o HLA type A*0201
o CMV and/ or EBV seropositivity
o Written informed consent
- Exclusion criteria- Disease specific treatment foreseen in the first 6 months after SCT
- Life expectation < 6 months.
- End stage irreversible multi-system organ failure (need for mechanical ventilation, hypotension for which admission to ICU, hepatic encephalopathy, coma).
- Pregnant or lactating women or women with child bearing potential who are unwilling or not capable to use effective means of birth control.
- Severe psychological disturbances.
- mec approval receivedyes
- multicenter trialno
- randomisedno
- group[default]
- TypeSingle arm
- Studytypeintervention
- planned startdate 1-okt-2014
- planned closingdate1-okt-2016
- Target number of participants17
- Interventionsderived multi-antigen specific T cells
- Primary outcomeTo evaluate the efficacy of the transfer of multiantigen specific T cells by measuring the appearance or expansion (if antigenic specific donor derived cells are already present in the circulation of the patient at time of infusion) of antigen specific donor derived T cells during eight weeks after the infusion of donor derived multi antigen specific T cells.
- Secondary outcomeTo assess the feasibility and safety (toxicity) of the administration of donor derived multi antigen specific T cells early after T cell depleted allo-SCT.
- TimepointsEvery week during first 8 weeks. Thereafter every two weeks until 20 weeks after allo-SCT.
- Trial web site
- statusplanned
- CONTACT FOR PUBLIC QUERIESDr. C.J.M. Halkes
- CONTACT for SCIENTIFIC QUERIESProf. Dr. J.H.F. Falkenburg
- Sponsor/Initiator Leiden University Medical Center (LUMC)
- Funding
(Source(s) of Monetary or Material Support)
European Union
- Publications
- Brief summaryThis is a non-randomized phase I/II study to analyze the feasibility and safety of administration of multiantigen-specific T cells generated using sets of multiantigen-specific streptamers based on the patients and donors HLA type for the prevention of infectious complications and early relapse or disease progression after T cell depleted allo-SCT. Only patients with HLA type A*0201 will be included since at present only streptamers specific for the TAA and MiHA in the context of HLA-A2 are available, necessary for evaluation of the immunological endpoints of the study. As part of a European collaborative project T-Control, the same study will be performed at 2 centers in Europe in two different patient cohorts after T cell depleted allo-SCT to allow appropriate evaluation of the potential broad applicability of this therapy. We aim to evaluate the effects of this intervention in 17 patients treated at the Leiden University Medical Center (LUMC) following allo-SCT with in-vitro T cell depletion using alemtuzumab. Seventeen patients will be treated at the Wurzburg University Medical Center following allo-SCT using CD34 selection for in-vitro T cell depletion.
- Main changes (audit trail)
- RECORD22-sep-2014 - 15-okt-2014


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl